Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

carrimycin

A 16-membered macrolide antibiotic, with potential antibacterial and immunomodulatory activities. Upon administration, carrimycin targets and binds to bacterial ribosomes, thereby inhibiting protein synthesis. Carrimycin may be active against some Gram-positive bacteria and Mycobacterium tuberculosis. It may also have immunomodulatory activity, presumably through a different mechanism, which has not yet been characterized.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	biotechspiramycin shengjimycin
Foreign brand name:	Bite

carrimycin

Search NCI's Drug Dictionary